P

Pfizer

Makes cancer drugs, vaccines and other medicines

Lung Cancer MAS - Oncology Field Medical Affairs

Full-TimeUpdated on 10/15/2026
No salary listed
Mid
Bachelor's, Master's, PhD, MD
Tokyo, Japan
HybridField and head-office work mix varies by role and business needs; some roles may be entirely field-based.
Biology & Biotech

About the job

Requirements
  • A four-year university undergraduate degree and a master's degree in life science, or one of the specified pharmacist, nurse, veterinarian, dentist, or medical-doctor education pathways.
  • Medical and pharmaceutical expert knowledge of the therapeutic disease area and products.
  • Ability to communicate appropriately and build relationships with internal and external stakeholders.
  • Ability to collaborate effectively across teams and functions.
  • Ability to conduct medical discussions with relevant departments and external healthcare professionals.
  • Understanding of compliance and relevant pharmaceutical-industry laws and regulations, and advocacy for appropriate product use.
  • Understanding of the internal organization, key stakeholders, and strategies.
  • Ability to acquire necessary medical and scientific knowledge and skills through self-learning.
  • Ability to understand written and spoken English and Japanese in the assigned therapeutic disease area and scientific interactions.
  • Minimum TOEIC score of 730.
Responsibilities
  • Serve as Pfizer Japan's medical and scientific point of contact for healthcare professionals, medical societies, regulators, academia, and other external stakeholders.
  • Provide scientific and medical leadership and expertise during internal and external activities.
  • Develop local medical plans aligned with global plans to address local unmet medical needs and data gaps, and contribute to local medical strategies and lifecycle clinical plans for inline and pipeline medicines and vaccines.
  • Exchange medical and scientific information with medical facilities and external stakeholders and contribute to medical-strategy decisions that support safe, proper, and effective product use.
  • Increase understanding of disease burden and product medical attributes to support safe and efficacious use.
  • Contribute to department and team goals, participate as a core member in cross-organizational projects, and provide guidance to deliver results.
  • Identify unmet medical needs and healthcare disparities, and execute customer-facing activities including scientific communications, medical advisory boards, educational seminars, data-generation initiatives, medical-material creation, and scientific input.
  • Create activity plans with senior medical management to address unmet needs and data gaps.
  • Develop the customer-facing portion of medical plans and establish collaborative scientific relationships with stakeholders.
  • Provide subject-matter expertise and scientific exchange, and bring stakeholder insights into the organization to shape strategy.
  • Build scientific relationships through non-promotional exchanges, including discussion of current research papers and academic-conference presentations.
  • Maintain stakeholder maps and communicate effectively with healthcare professionals, medical societies, and other external stakeholders.
  • Follow up on investigator-sponsored research and medical grants in accordance with Pfizer policies.
  • Maintain current medical and pharmaceutical information to identify unmet needs and support medical strategy.
  • Deliver activities in medical plans, including educational materials, real-world evidence, non-interventional studies, database studies, and registries, and support timely publication of data.
  • Share customer insights with internal and external stakeholders to support evidence creation and cross-functional partnerships.
  • Apply patient-centricity, health-literacy, and cultural-awareness principles in medical communications and deliverables.
  • Build peer-to-peer scientific relationships with leading healthcare professionals and specialists, including non-traditional partners and key decision-makers.
  • Maintain and enhance cross-business-unit alignment on metrics.
  • Collect and analyze information and insights before meetings with stakeholders and healthcare professionals.
  • Provide relevant stakeholder feedback on product lifecycle strategies to company divisions and departments.
  • Share appropriate medical and scientific information and insights with marketing colleagues for brand planning.
  • Provide scientific input for scientific meetings and materials.
  • Provide medical-education programs with medical societies and relevant stakeholders.
  • Provide medical and scientific input into clinical-trial protocol feasibility assessments.
  • Collaborate with Japan and global development teams to identify investigators and sites for Pfizer-sponsored clinical trials.
  • Work with clinical research and development colleagues to drive timely completion of Pfizer-sponsored clinical trials.
  • Provide scientific and medical leadership and input to global clinical teams and Japan development teams to ensure trials reflect Japan's needs and support early development and regulatory interactions.
  • Contribute to product and therapeutic-area medical strategies and provide internal and external medical and scientific advice to support appropriate product use and patient safety.
  • Provide accurate, high-quality, unbiased medical information to healthcare professionals and external experts, including responding to unsolicited medical requests.
  • Provide scientific insight and support to field- and head-office-based commercial colleagues.
  • Collaborate with in-country and above-country cross-functional teams to develop impactful, compliant promotional and non-promotional materials.
  • Collect and share stakeholder insights to inform medical strategy and business opportunities.
  • Manage local advisory boards to gather customer insights.
  • If media-trained, present the scientific perspective on selected topics during media briefings.
  • Follow the Medical Affairs code of conduct and guidance for external medical interactions, and provide promotional or non-promotional explanations as appropriate to related departments.
  • Conduct activities in compliance with applicable Japanese health-ministry guidelines, policies, and regulations.
  • Report safety information for Pfizer products in accordance with applicable laws, regulations, and Pfizer policy, and attend required safety-reporting training.
  • As needed, collaborate with Japan medical leadership, global medical-affairs members, and relevant functions to identify unmet needs and candidate therapies for potential medical interventions in Japan, maintaining confidentiality.
  • As needed, respond rapidly to critical supply issues from a medical perspective, including communications with academic societies and regulatory authorities.
Desired Qualifications
  • Medical doctor with clinical experience; board certification is preferred.
  • PhD in life science.
  • Medical Affairs or Japan development experience, and/or research experience.
  • Scientific publication experience.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.

Yahoo Finance
Oct 12th, 2026
UPS, Pfizer, Kraft Heinz and Ford dividends at risk as payouts outstrip earnings

Four blue chip companies, UPS, Pfizer, Kraft Heinz, and Ford, may struggle to sustain their dividends, according to an analysis of their earnings, cash flow, and debt. UPS yields 7.02% and pays out about 121% of its GAAP earnings. Pfizer yields 6.10%, with a GAAP payout ratio of about 226%; its 2025 free cash flow of $9.076 billion fell short of $9.771 billion in dividends. Kraft Heinz yields 6.82%, but its trailing GAAP earnings per share are −$2.88 after $7.4 billion in impairments. Ford yields 4.98% after an $8.162 billion loss in 2025, and its debt-to-equity ratio is 4.66. All four companies say their payouts are safe, and each points to adjusted earnings guidance that covers the dividend.

Business Wire
Oct 7th, 2026
Pfizer's TUKYSA wins FDA approval for front-line HER2+ metastatic breast cancer maintenance treatment

The FDA has approved Pfizer's TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab for front-line maintenance treatment of adults with HER2-positive metastatic breast cancer. This chemotherapy-free option expands TUKYSA's use to an earlier disease stage. The approval follows Phase 3 HER2CLIMB-05 trial results showing median progression-free survival of 24.9 months versus 16.3 months with placebo—8.6 additional months without disease progression. The treatment reduced risk of progression or death by 35.9%. Most common adverse events included diarrhoea, musculoskeletal pain, hepatotoxicity, nausea, fatigue, rash, and vomiting. One fatal case of drug-induced liver injury occurred. TUKYSA was previously approved for second-line HER2-positive metastatic breast cancer treatment in 2020. HER2 is overexpressed in 15-20% of breast cancers.

Yahoo Finance
Oct 7th, 2026
Buffett indicator hits 235.8% as Oracle warns investors 'playing with fire' — 3 undervalued stocks to buy

Warren Buffett's favourite valuation metric, the ratio of total market capitalisation to GDP, has reached 235.8%, well above the 200% level he warned constitutes "playing with fire". The indicator sits near its record high from September 2026. Despite elevated overall market valuations, three stocks remain attractively priced. Enterprise Products Partners trades at 11.9 times forward earnings whilst offering a 6% distribution yield, benefiting from increased natural gas demand from AI data centres. JPMorgan Chase trades at 13.5 times forward earnings and could benefit from rising interest rates. Pfizer trades at just 9.7 times forward earnings with a 6.3% dividend yield, though it faces patent cliff challenges through 2028.